T1	PROC 44 100	Ensayo clínico de bajo nivel de intervención, de fase IV
T2	PROC 107 134	comparar la inmunogenicidad
T3	CHEM 215 221	vacuna
#1	AnnotatorNotes T3	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	DISO 195 206	hepatitis B
#2	AnnotatorNotes T4	C0019163; Hepatitis B; Disease or Syndrome
T5	CHEM 239 249	antigénica
#3	AnnotatorNotes T5	C0003320; Antigens; Immunologic Factor
T6	DISO 274 313	Enfermedades reumatológicas autoinmunes
T7	CHEM 327 336	rituximab
#4	AnnotatorNotes T7	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	DISO 339 365	cáncer de mama y de pulmón
T9	ANAT 359 365	pulmón
#5	AnnotatorNotes T9	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T10	DISO 394 433	Enfermedades reumatológicas autoinmunes
T11	PROC 437 448	tratamiento
#6	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	DISO 466 492	cáncer de mama y de pulmón
T13	ANAT 486 492	pulmón
#7	AnnotatorNotes T13	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T14	PROC 496 525	tratamiento con quimioterapia
T15	PROC 592 606	diagnosticados
#8	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 615 650	Enfermedad reumatológica autoinmune
T17	CHEM 672 681	Rituximab
#9	AnnotatorNotes T17	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T18	ANAT 694 698	mama
#10	AnnotatorNotes T18	C0006141; Breast; Body Part, Organ, or Organ Component | C1268990; Entire breast; Body Part, Organ, or Organ Component
T19	ANAT 701 707	pulmón
#11	AnnotatorNotes T19	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T20	DISO 684 707	Cancer de mama o pulmón
T21	DISO 763 774	hepatitis B
#12	AnnotatorNotes T21	C0019163; Hepatitis B; Disease or Syndrome
T22	PROC 776 796	anticuerpos anti-HBV
#13	AnnotatorNotes T22	C0201480; Hepatitis B core antibody measurement; Laboratory Procedure
T23	PROC 798 853	antígenos de superficie para el virus de la hepatitis B
#14	AnnotatorNotes T23	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T24	PROC 856 905	anticuerpos anti-HBV para antígenos de superficie
T25	PROC 746 774	marcadores de la hepatitis B
#15	AnnotatorNotes T25	C2030661; serum hepatitis B markers; Laboratory Procedure
T26	PROC 1044 1055;977 1001	por escrito Consentimiento informado
#16	AnnotatorNotes T26	C0811741; Obtain informed written consent; Health Care Activity
T27	DISO 1083 1090	Alergia
#17	AnnotatorNotes T27	C1527304; Allergic Reaction; Pathologic Function
T28	CHEM 1122 1133	excipientes
#18	AnnotatorNotes T28	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T29	PROC 1164 1175	tratamiento
#19	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 1191 1200	infección
#20	AnnotatorNotes T30	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T31	CHEM 1228 1256	vacuna contra la hepatitis B
#21	AnnotatorNotes T31	C0062527; hepatitis B surface antigen vaccine; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	DISO 1272 1289	Infección por HIV
#22	AnnotatorNotes T32	C0019693; HIV Infections; Disease or Syndrome
T33	PROC 1307 1337	vacunado contra la Hepatitis B
#23	AnnotatorNotes T33	C0474232; Hepatitis B vaccination; Therapeutic or Preventive Procedure
T34	DISO 1326 1337	Hepatitis B
#24	AnnotatorNotes T34	C0019163; Hepatitis B; Disease or Syndrome
T35	DISO 1423 1445	enfermedad inmunitaria
T36	PROC 1479 1490	diagnóstico
#25	AnnotatorNotes T36	C0011900; Diagnosis; Diagnostic Procedure
T37	CHEM 172 206	vacuna adyuvada contra hepatitis B
T38	PROC 314 322	tratadas
#26	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T39	ANAT 349 353	mama
#27	AnnotatorNotes T39	C0006141; Breast; Body Part, Organ, or Organ Component | C1268990; Entire breast; Body Part, Organ, or Organ Component
T40	CHEM 453 462	rituximab
#28	AnnotatorNotes T40	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T41	ANAT 476 480	mama
#29	AnnotatorNotes T41	C0006141; Breast; Body Part, Organ, or Organ Component | C1268990; Entire breast; Body Part, Organ, or Organ Component
T42	PROC 656 667	tratamiento
#30	AnnotatorNotes T42	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T43	CHEM 1101 1119	compuestos activos
#31	AnnotatorNotes T43	C1372955; active ingredients; Chemical Viewed Functionally
T44	CHEM 1152 1159	vacunas
#32	AnnotatorNotes T44	C0042210; Vaccines; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T45	DISO 1245 1256	hepatitis B
#33	AnnotatorNotes T45	C0019163; Hepatitis B; Disease or Syndrome
T46	Date 12 16	2018
T47	LIVB 138 147	pacientes
#34	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	LIVB 554 563	Pacientes
#35	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T50	Age 564 581	mayores a 18 años
T52	LIVB 793 796	HBV
#36	AnnotatorNotes T52	C0019169; hepatitis B virus; Virus
T53	LIVB 830 853	virus de la hepatitis B
#37	AnnotatorNotes T53	C0019169; hepatitis B virus; Virus
T54	LIVB 873 876	HBV
#38	AnnotatorNotes T54	C0019169; hepatitis B virus; Virus
T55	Duration 917 936	los 3 últimos meses
T56	Duration 958 974	superior a 1 año
T57	LIVB 1006 1014	paciente
#39	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Neg_cue 1293 1295	No
T59	LIVB 1355 1363	paciente
#40	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 1286 1289	HIV
#41	AnnotatorNotes T60	C0019682; HIV; Virus
T61	ANAT 1434 1445	inmunitaria
#42	AnnotatorNotes T61	C0020962; Immune system; Body System | C1305754; Entire immune system; Body System
T49	PROC 1375 1382	visitas
#43	AnnotatorNotes T49	C1512346; Patient Visit; Health Care Activity
T51	Observation 1340 1350;1364 1382	Dificultad a ir a las visitas
#44	AnnotatorNotes T51	C0589126; Patient defaulted from follow-up; Finding (?)
A1	Assertion T33 Negated
A2	Status T27 History_of
A3	Status T30 History_of
A4	Status T31 History_of
#45	AnnotatorNotes T6	C1328842; autoimmune rheumatologic disease; Disease or Syndrome 
#46	AnnotatorNotes T10	C1328842; autoimmune rheumatologic disease; Disease or Syndrome 
#47	AnnotatorNotes T16	C1328842; autoimmune rheumatologic disease; Disease or Syndrome 
#48	AnnotatorNotes T12	C0006142; Malignant neoplasm of breast; Neoplastic Process | C0678222; Breast Carcinoma; Neoplastic Process + C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
#49	AnnotatorNotes T8	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
#50	AnnotatorNotes T14	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure + C3665472; Chemotherapy; Therapeutic or Preventive Procedure
#51	AnnotatorNotes T20	C0006142; Malignant neoplasm of breast; Neoplastic Process | C0678222; Breast Carcinoma; Neoplastic Process + C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
#52	AnnotatorNotes T35	C0021053; Immune System Diseases; Disease or Syndrome
#53	AnnotatorNotes T2	C4054739; Immunogenicity Study; Research Activity
R1	Negation Arg1:T58 Arg2:T33	
R2	Experiences Arg1:T47 Arg2:T37	
R3	Experiences Arg1:T47 Arg2:T3	
T62	DISO 148 164	inmunosupresores
#54	AnnotatorNotes T62	C4048329; Immunosuppression; Disease or Syndrome
R4	Experiences Arg1:T47 Arg2:T62	
T63	Quantifier_or_Qualifier 222 249	de elevada carga antigénica
R5	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T63	
R6	Used_for Arg1:T7 Arg2:T38	
R7	Location_of Arg1:T39 Arg2:T8	
R8	Location_of Arg1:T9 Arg2:T8	
R9	Overlap Arg1:T6 Arg2:T8	
R10	Used_for Arg1:T40 Arg2:T11	
R11	Location_of Arg1:T41 Arg2:T12	
R12	Location_of Arg1:T13 Arg2:T12	
R13	Has_Age Arg1:T48 Arg2:T50	
R14	Used_for Arg1:T17 Arg2:T42	
R15	Location_of Arg1:T18 Arg2:T20	
R16	Location_of Arg1:T19 Arg2:T20	
T64	Quantifier_or_Qualifier 708 717	primarios
#55	AnnotatorNotes T64	C0205225; Primary; Qualitative Concept
R17	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T64	
T65	Result_or_Value 720 740	Resultados negativos
#56	AnnotatorNotes T65	C0205160; Negative; Finding
R18	Has_Result_or_Value Arg1:T25 Arg2:T65	
R19	Has_Result_or_Value Arg1:T22 Arg2:T65	
R20	Has_Result_or_Value Arg1:T23 Arg2:T65	
R21	Has_Result_or_Value Arg1:T24 Arg2:T65	
R22	Overlap Arg1:T24 Arg2:T55	
R23	Overlap Arg1:T25 Arg2:T55	
R24	Overlap Arg1:T22 Arg2:T55	
R25	Overlap Arg1:T23 Arg2:T55	
T66	CONC 940 957	Esperanza de vida
#57	AnnotatorNotes T66	C0023671; Life Expectancy; Group Attribute
R26	Has_Duration_or_Interval Arg1:T66 Arg2:T56	
T67	Observation 1020 1043	participar en el ensayo
#58	AnnotatorNotes T67	C1278516; Patient participation status; Finding
R27	Before Arg1:T26 Arg2:T67	
R28	Causes Arg1:T43 Arg2:T27	
R29	Causes Arg1:T28 Arg2:T27	
R30	Causes Arg1:T44 Arg2:T27	
R31	Used_for Arg1:T44 Arg2:T29	
R32	Causes Arg1:T60 Arg2:T32	
T68	Observation 1296 1302	querer
#59	AnnotatorNotes T68	C0600109; Willing; Finding
R33	Negation Arg1:T58 Arg2:T68	
A5	Assertion T68 Negated
R34	Experiences Arg1:T59 Arg2:T51	
R35	Location_of Arg1:T61 Arg2:T35	
T69	Quantifier_or_Qualifier 1418 1422	otra
#60	AnnotatorNotes T69	C0205394; Other; Qualitative Concept
R36	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T69	
T70	Quantifier_or_Qualifier 1472 1478	primer
#61	AnnotatorNotes T70	C0205435; First (number); Quantitative Concept
R37	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T70	
R38	Before Arg1:T36 Arg2:T35	
R39	Overlap Arg1:T68 Arg2:T33	
A6	Experiencer T47 Patient
A7	Experiencer T48 Patient
A8	Experiencer T57 Patient
A9	Experiencer T59 Patient
